Nabij-infrarood lichttherapie-apparaat voor milde tot matige ziekte van Alzheimer (NirsCure-03A)
Een multicenter, gerandomiseerd, dubbelblind, sham-gecontroleerd onderzoek naar de werkzaamheid en veiligheid van een nabij-infrarood lichttherapie-apparaat bij deelnemers met milde tot matige ziekte van Alzheimer (NirsCure-03A)
This study is a multicenter, randomized, double-blind, sham-device-controlled clinical trial.
A total of 320 patients with mild to moderate Alzheimer's disease (AD) are planned to be enrolled. Central stratified block randomization will be applied, with stratification based on disease severity (mild vs. moderate) and Aβ-PET subgroup center status (yes vs. no). Participants will be randomly assigned to either the treatment group or control group in a 1:1 ratio. After enrollment, participants will complete the treatment at home during a 52-week double-blind period. The treatment group will receive therapy using a near-infrared light therapy device, while the control group will use sham device. Both investigators and participants will remain blinded to treatment allocation throughout the double-blind period. Participants who complete the 52-week double-blind treatment period may choose to enter an open-label extension and receive an additional 26 weeks of active near-infrared light therapy.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Yi Tang, MD, PhD
- Telefoonnummer: +86 13811021432
- E-mail: tangyi@xwhosp.org
Studie Locaties
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100191
- Werving
- Peking University Third Hospital
-
Contact:
- Weizhong Xiao, MD, PhD
- Telefoonnummer: +86 15611908691
-
Beijing, Beijing Municipality, China, 100053
- Werving
- Xuanwu Hospital, Capital Medical University
-
Contact:
- Yi Tang, MD, PhD
- Telefoonnummer: +86 13811021432
- E-mail: tangyi@xwhosp.org
-
Beijing, Beijing Municipality, China, 100032
- Werving
- Peking University First Hospital
-
Contact:
- Yongan Sun, MD, PhD
- Telefoonnummer: +86 13391705678
-
Beijing, Beijing Municipality, China, 100730
- Werving
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
-
Contact:
- Jing Yuan, MD, PhD
- Telefoonnummer: +86 18601105034
-
Beijing, Beijing Municipality, China, 100050
- Werving
- Beijing Friendship Hospital, Capital Medical University
-
Contact:
- Yongbo Zhang, MD, PhD
- Telefoonnummer: +86 13552909549
-
-
Hebei
-
Shijiazhuang, Hebei, China, 050000
- Werving
- Shijiazhuang People's Hospital
-
Contact:
- Jianping Zhang, MD, PhD
- Telefoonnummer: +86 17603116783
-
-
Inner Mongolia
-
Baotou, Inner Mongolia, China, 014040
- Werving
- Baotou Central Hospital
-
Contact:
- Furu Liang, MD, PhD
- Telefoonnummer: +86 13664077877
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215006
- Werving
- The First Affiliated Hospital of Soochow University
-
Contact:
- Qun Xue, MD, PhD
- Telefoonnummer: +86 13013813620
-
Suzhou, Jiangsu, China, 215004
- Werving
- The Second Affiliated Hospital of Soochow University
-
Contact:
- Chunfeng Liu, MD, PhD
- Telefoonnummer: +86 13606210609
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710061
- Werving
- The First Affiliated Hospital of Xi'an Jiaotong University
-
Contact:
- Jin Wang, MD, PhD
- Telefoonnummer: +86 13572208524
-
Xi'an, Shaanxi, China, 710068
- Werving
- Shaanxi Provincial People's Hospital
-
Contact:
- Rui Li, MD, PhD
-
Xi'an, Shaanxi, China, 710038
- Werving
- Tangdu Hospital, Air Force Medical University
-
Contact:
- Wei Zhang, MD， PhD
- Telefoonnummer: +86 13891955100
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200127
- Werving
- Renji Hospital, Shanghai Jiao Tong University School of Medicine
-
Contact:
- Qun Xu, MD, PhD
- Telefoonnummer: +86 13301679717
-
Shanghai, Shanghai Municipality, China, 200040
- Werving
- Huashan Hospital, Fudan University
-
Contact:
- Qianhua Zhao, MD, PhD
-
Shanghai, Shanghai Municipality, China, 200030
- Werving
- Shanghai Mental Health Center
-
Contact:
- Xia Li, MD, PhD
- Telefoonnummer: +86 13774272543
-
Shanghai, Shanghai Municipality, China, 201399
- Werving
- Pudong Hospital, Fudan University
-
Contact:
- Yunxia Li, MD, PhD
- Telefoonnummer: +86 13636370312
-
-
Shanxi
-
Taiyuan, Shanxi, China, 030001
- Werving
- The First Hospital of Shanxi Medical University
-
Contact:
- Yang Li, MD, PhD
- Telefoonnummer: +86 15035182003
-
Taiyuan, Shanxi, China, 030001
- Werving
- Shanxi Bethune Hospital
-
Contact:
- Xiaolei Liu, MD, PhD
- Telefoonnummer: +86 13934643261
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 300052
- Werving
- General Hospital, Tianjin Medical University
-
Contact:
- Nan Zhang, MD, PhD
- Telefoonnummer: +86 13752128310
-
Tianjin, Tianjin Municipality, China, 300060
- Werving
- Tianjin Huanhu Hospital
-
Contact:
- Pan Li, MD, PhD
- Telefoonnummer: +86 13114881943
-
Tianjin, Tianjin Municipality, China, 300121
- Werving
- Tianjin People's Hospital
-
Contact:
- Meiyun Zhang, MD, PhD
- Telefoonnummer: +86 13102017703
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310009
- Werving
- The Second Affiliated Hospital, Zhejiang University School of Medicine
-
Contact:
- Baorong Zhang, MD, PhD
- Telefoonnummer: +86 13958167260
-
Hangzhou, Zhejiang, China, 310015
- Werving
- Affiliated Hospital of Hangzhou Normal University
-
Contact:
- Jinghua Wang, MD, PhD
- Telefoonnummer: +86 15068892292
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Male or female participants aged between 50 to 85 years old (inclusive).
-
Participants must have at least 4 years of formal education and be capable of completing cognitive and other protocol-specified assessments.
-
Documented progressive memory decline for ≥12 months prior to screening.
-
Meets the core clinical diagnostic criteria for mild to moderate AD dementia (stages 4-5), according to the National Institute on Aging and the Alzheimer's Association (NIA-AA) 2018 research framework and the AA workgroup 2024 update.
-
Evidence of positive brain amyloid pathology, demonstrated by at least one of the following:
- Positive Aβ-PET scan (historical positive result acceptable); or
- Positive Cerebrospinal fluid (CSF) Aβ testing (historical positive result acceptable).
-
Mini-Mental State Examination (MMSE) total score between 15 and 26 inclusive (between 12 and 22 for participants with an elementary school education level).
-
Clinical Dementia Rating (CDR) Global of 1 or 2, and the CDR-Memory Box scores ≥ 0.5.
-
If receiving acetylcholinesterase inhibitor or memantine, participants must be on a stable dose for at least 12 weeks prior to baseline.
-
Must have at least one reliable study partner who can accompany the participant to complete daily treatment. The study partner should have a close relationship with the participant and sufficient knowledge to accurately report on cognition, function, behavior, safety, and protocol compliance. The study partner must be able to communicate with study staff via phone or WeChat, attend required on-site visit, provide informed consent to supporting follow-up throughout the study.
-
The participant, study partner, or legally authorized representative voluntarily agrees to participate and provides written informed consent prior to any study procedures.
Exclusion Criteria:
-
Presence of any diagnosis other than AD that could cause dementia or cognitive decline, including but not limited to: vascular dementia; Central nervous system infections (e.g., HIV, neurosyphilis); Creutzfeldt-Jakob disease; Huntington's disease; Parkinson's disease; Lewy body dementia; Traumatic brain injury-related dementia; Dementia caused by physical and chemical factors (e.g., drug toxicity, alcohol intoxication, carbon monoxide poisoning); significant systemic diseases (e.g., hepatic or pulmonary encephalopathy); Intracranial space-occupying lesions (e.g., subdural hematoma, brain tumors); or dementia clearly attributable to endocrine disorders, vitamin deficiencies, or other identifiable causes.
-
Brain MRI demonstrating significant pathological findings, including but not limited to:
- More than two infarcts with a diameter > 2 cm, or a single infarct involving critical regions (thalamus, hippocampus, entorhinal cortex, parahippocampal cortex, angular gyrus, or other cortical and subcortical gray matter nuclei);
- Extensive white matter hyperintensities (Fazekas score ≥ 3);
- Space-occupying lesions such as abscesses or brain tumors. Lesions judged by the investigator to have no clear clinical significance do not require exclusion.
-
History of transient ischemic attack (TIA), stroke, or seizure within 6 months of screening.
-
Hachinski Ischemic Score (HIS) > 4.
-
Hamilton Depression Rating Scale (HAMD-17) total score > 10.
-
Diagnosis of a psychiatric disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) at screening, including schizophrenia or other psychotic disorders, bipolar disorder, major depressive disorder, or delirium.
-
Known history or laboratory confirmation of HIV infection or neurosyphilis at screening.
-
Severe cardiovascular disease, including New York Heart Association (NYHA) class III or IV heart function; Severe or unstable angina, or newly developed unstable angina within 3 months prior to screening (with objective clinical evidence such as cardiac enzyme abnormalities or dynamic ST-T changes on electrocardiogram); Acute myocardial infarction within 6 months prior to screening.
-
Severe dysfunction of major organs (heart, lungs, liver, kidneys, etc.), or any medical condition that, in the opinion of the investigator, could render the participant unsuitable for this study or interfere with participation.
-
Current or prior treatment with any anti-amyloid monoclonal antibody (e.g., aducanumab, lecanemab, or donanemab).
-
Prior or planned lymphaticovenous anastomosis (LVA) of the cervical deep lymphatic vessels.
-
Participation in any interventional clinical trial involving a drug or medical device within the 30 days prior to screening, except for observational studies or verified placebo-group participation in a previous interventional trial.
-
History of severe head trauma or implanted cranial devices (e.g., bone screws, bone plates, prior cranial surgery, deep brain stimulators); Contraindications to MRI (e.g., claustrophobia, pacemakers/defibrillators, ferromagnetic metal implants); unwilling to undergo MRI examination.
-
Contraindications to PET or allergy to Aβ-PET tracer (except participants enrolled based solely on CSF Aβ positivity). Participants with uncontrolled abnormal blood glucose, allergy to FDG tracer, or any other investigator-judged contraindications are ineligible for the FDG-PET substudy.
-
History of malignancy within 5 years prior to screening, except for:
- Adequately treated basal or squamous cell skin carcinoma, or cervical dysplasia;
- Adequately treated Stage I in situ cervical cancer ≥ 2 years prior to screening without recurrence;
- Prostate cancer confined to the prostate, adequately treated (e.g., surgery, radiotherapy, or active surveillance), with stable prostate-specific antigen (PSA) levels for ≥ 2 years prior to screening;
- Non-metastatic breast cancer, adequately treated and without recurrence.
-
Women who are pregnant, breastfeeding, planning pregnancy, or of childbearing potential not using highly effective contraception.
-
Any other condition that, in the opinion of the investigator, may compromise the participant's safety, interfere with protocol adherence, or confound study results.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Sham-vergelijker: Sham device
Device: NirsCure 6000 sham device (once daily for 30 minutes, six times per week) |
Sham device for 52 weeks during the double-blind period (once daily for 30 minutes, six times per week). Participants entering the open-label extension will receive active near-infrared light therapy for an additional 26 weeks. |
|
Experimenteel: Near infrared light therapy
Device: NirsCure 6000 Near-infrared light therapy (once daily for 30 minutes, six times per week) |
Near-infrared light therapy for 52 weeks during the double-blind period (once daily for 30 minutes, six times per week). Participants entering the open-label extension will receive an additional 26 weeks of active treatment with the same regimen. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Alzheimer's Disease Assessment Scale, cognitive subscale 13 (ADAS-Cog13)
Tijdsspanne: 52 weeks
|
Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-Cog13) score at 52-Weeks. The ADAS-Cog13 score ranges from 0 to 85, with higher scores indicating greater cognitive impairment. |
52 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Integrated Alzheimer's Disease Rating Scale (iADRS)
Tijdsspanne: 52 weeks
|
Change from baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) score at 52-Weeks. The iADRS score ranges from 0 to 144, with higher scores indicating better overall cognitive and functional performance. |
52 weeks
|
|
Alzheimer's Disease Cooperative Study Activities of Daily Living Scale (ADCS-ADL)
Tijdsspanne: 52 weeks
|
Change from baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) score at 52-Weeks. The ADCS-ADL score ranges from 0 to 78, with higher scores indicating better functional ability in activities of daily living. |
52 weeks
|
|
Clinical Dementia Rating - Sum of Boxes (CDR-SB)
Tijdsspanne: 52 weeks
|
Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) score at 52-Weeks. The CDR-SB score ranges from 0 to 18, with higher scores indicating greater cognitive and functional impairment. |
52 weeks
|
|
Mini-Mental Status Examination (MMSE)
Tijdsspanne: 52 weeks
|
Change from baseline in Mini-Mental State Examination (MMSE) score at 52-Weeks. The MMSE score ranges from 0 to 30, with higher scores indicating better cognitive function. |
52 weeks
|
|
ADAS-Cog13
Tijdsspanne: 13, 26 and 39 weeks
|
Change from baseline in the ADAS-Cog13 at Week 13, 26 and 39 |
13, 26 and 39 weeks
|
|
ADAS-Cog13
Tijdsspanne: 81 weeks
|
Change from baseline in the ADAS-Cog13 at Week 81 |
81 weeks
|
|
iADRS
Tijdsspanne: 81 weeks
|
Change from baseline in the iADRS at Week 81 |
81 weeks
|
|
ADCS-ADL
Tijdsspanne: 81 weeks
|
Change from baseline in the ADCS-ADL at Week 81 |
81 weeks
|
|
CDR-SB
Tijdsspanne: 81 weeks
|
Change from baseline in the CDR-SB at Week 81 |
81 weeks
|
|
MMSE
Tijdsspanne: 81 weeks
|
Change from baseline in the MMSE at Week 81 |
81 weeks
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- NirsCure-03A
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .